Star Tribune, October 26, 2012

A US Senate Finance Committee report alleges that Medtronic was heavily involved in drafting, editing and shaping the content of medical journal articles authored by its physician consultants involving its InFuse bone growth product used in spine surgery. This information was not disclosed, raising serious questions about the research conducted. Medtronic was paid $210 million over several years through royalties and consulting fees.

Facebook icon
LinkedIn icon
Twitter icon